A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel® with CPG 7909, using two different formulations and dosing intervals
- 24 June 2009
- Vol. 27 (31) , 4104-4109
- https://doi.org/10.1016/j.vaccine.2009.04.077
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in MaliVaccine, 2009
- Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of AgeNew England Journal of Medicine, 2008
- Phase 1 Trial of AMA1-C1/Alhydrogel plus CPG 7909: An Asexual Blood-Stage Vaccine for Plasmodium falciparum MalariaPLOS ONE, 2008
- Protection Induced by Plasmodium falciparum MSP142 Is Strain-Specific, Antigen and Adjuvant Dependent, and Correlates with Antibody ResponsesPLOS ONE, 2008
- Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccinesVaccine, 2008
- Impact of a Plasmodium falciparum AMA1 Vaccine on Antibody Responses in Adult MaliansPLOS ONE, 2007
- Structural basis of antigenic escape of a malaria vaccine candidateProceedings of the National Academy of Sciences, 2007
- Enhanced antibody production in mice to the malaria antigen AMA1 by CPG 7909 requires physical association of CpG and antigenVaccine, 2007
- Formulation of vaccines containing CpG oligonucleotides and alumJournal of Immunological Methods, 2007
- Immunity to RecombinantPlasmodium falciparumMerozoite Surface Protein 1 (MSP1): Protection inAotus nancymaiMonkeys Strongly Correlates with Anti-MSP1 Antibody Titer and In Vitro Parasite-Inhibitory ActivityInfection and Immunity, 2006